These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 20032006

  • 1. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C.
    Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, Rodriguez-Novoa S, Alvarez E, Jimenez-Nacher I, Soriano V.
    J Antimicrob Chemother; 2010 Mar; 65(3):543-7. PubMed ID: 20032006
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Unboosted fosamprenavir is associated with low drug exposure in HIV-infected patients with mild-moderate liver impairment resulting from HCV-related cirrhosis.
    Gatti F, Nasta P, Loregian A, Puoti M, Matti A, Pagni S, de Requena DG, Prestini K, Parisi SG, Bonora S, Palù G, Carosi G.
    J Antimicrob Chemother; 2009 Mar; 63(3):575-8. PubMed ID: 19151039
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Influence of insulin resistance on hepatic fibrosis and steatosis in hepatitis C virus (HCV) mono-infected compared with HIV-HCV co-infected patients.
    Halfon P, Pénaranda G, Carrat F, Bedossa P, Bourlière M, Ouzan D, Renou C, Tran A, Rosenthal E, Wartelle C, Delasalle P, Cacoub P.
    Aliment Pharmacol Ther; 2009 Jul; 30(1):61-70. PubMed ID: 19292832
    [Abstract] [Full Text] [Related]

  • 6. Mitigation of antiretroviral-induced hyperlipidemia by hepatitis C virus co-infection.
    Cooper CL, Mills E, Angel JB.
    AIDS; 2007 Jan 02; 21(1):71-6. PubMed ID: 17148970
    [Abstract] [Full Text] [Related]

  • 7. Is the increased risk of liver enzyme elevation in patients co-infected with HIV and hepatitis virus greater in those taking antiretroviral therapy?
    Cicconi P, Cozzi-Lepri A, Phillips A, Puoti M, Antonucci G, Manconi PE, Tositti G, Colangeli V, Lichtner M, Monforte Ad, ICoNA Study Group.
    AIDS; 2007 Mar 12; 21(5):599-606. PubMed ID: 17314522
    [Abstract] [Full Text] [Related]

  • 8. Liver fibrosis in patients with chronic hepatitis C and persistently normal liver enzymes: influence of HIV infection.
    Martin-Carbonero L, de Ledinghen V, Moreno A, Maida I, Foucher J, Barreiro P, Romero M, Satta G, Garcia-Samaniego J, Gonzalez-Lahoz J, Soriano V.
    J Viral Hepat; 2009 Nov 12; 16(11):790-5. PubMed ID: 19413693
    [Abstract] [Full Text] [Related]

  • 9. Antiretroviral treatment change among HIV, hepatitis B virus and hepatitis C virus co-infected patients in the Australian HIV Observational Database.
    Petoumenos K, Ringland C, Australian HIV Observational Database.
    HIV Med; 2005 May 12; 6(3):155-63. PubMed ID: 15876281
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Natural history and predictors of severity of chronic hepatitis C virus (HCV) and human immunodeficiency virus (HIV) co-infection.
    Vallet-Pichard A, Pol S.
    J Hepatol; 2006 May 12; 44(1 Suppl):S28-34. PubMed ID: 16343684
    [Abstract] [Full Text] [Related]

  • 12. Low-level liver enzyme elevations during HAART are not associated with liver fibrosis progression among HIV/HCV-coinfected patients.
    Vergara S, Macías J, Mira JA, García-García JA, Merchante N, del Valle J, Abdel-Kader L, Lozano F, Gómez-Mateos JM, Pineda JA.
    J Antimicrob Chemother; 2007 Jan 12; 59(1):87-91. PubMed ID: 17095528
    [Abstract] [Full Text] [Related]

  • 13. Influence of viral chronic hepatitis co-infection on plasma drug concentrations and liver transaminase elevations upon therapy switch in HIV-positive patients.
    Torti C, Lapadula G, Uccelli MC, Quiros-Roldan E, Regazzi M, Ladisa N, Micheli V, Orani A, Patroni A, Caputo SL, Tirelli V, Di Giambenedetto S, Cologni G, Costarelli S, Gargiulo F, Manca N, Carosi G, RADAR Study Group of MASTER Cohort.
    Int J Antimicrob Agents; 2007 Feb 12; 29(2):185-90. PubMed ID: 17011754
    [Abstract] [Full Text] [Related]

  • 14. Hepatic safety and tolerability of raltegravir among HIV patients coinfected with hepatitis B and/or C.
    Hurt CB, Napravnik S, Moore RD, Eron JJ.
    Antivir Ther; 2014 Feb 12; 19(4):415-22. PubMed ID: 24458137
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Intrahepatic mRNA expression in hepatitis C virus and HIV/hepatitis C virus co-infection: infiltrating cells, cytokines, and influence of HAART.
    Kuntzen T, Tural C, Li B, Feldmann G, Kupfer B, Nischalke HD, Clotet B, Sauerbruch T, Rockstroh JK, Spengler U.
    AIDS; 2008 Jan 11; 22(2):203-10. PubMed ID: 18097222
    [Abstract] [Full Text] [Related]

  • 17. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection.
    Rockstroh J, Teppler H, Zhao J, Sklar P, Harvey C, Strohmaier K, Leavitt R, Nguyen BY.
    HIV Med; 2012 Feb 11; 13(2):127-31. PubMed ID: 21599819
    [Abstract] [Full Text] [Related]

  • 18. Progression of fibrosis in HIV and hepatitis C virus-coinfected patients treated with interferon plus ribavirin-based therapy: analysis of risk factors.
    Bani-Sadr F, Lapidus N, Bedossa P, De Boever CM, Perronne C, Halfon P, Pol S, Carrat F, Cacoub P, French National Agency for Research on AIDS, Viral Hepatitis-HC02-Ribavic Study Team.
    Clin Infect Dis; 2008 Mar 01; 46(5):768-74. PubMed ID: 18248298
    [Abstract] [Full Text] [Related]

  • 19. Raltegravir: new Drug. Alternative to enfuvirtide/darunavir in multidrug-resistant HIV.
    Prescrire Int; 2008 Aug 01; 17(96):135-7. PubMed ID: 19480091
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.